Trisomy of Chromosome 8 is a frequent, non-specific finding in several myeloid neoplasms, including acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). This cytogenetic abnormality has prognostic implications.
In patients with MDS, trisomy 8 is associated with an intermediate prognosis. In patients with AML, trisomy 8 can be associated with intermediate or poor prognosis, depending on other cytogenetic abnormalities.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to specific regions of Chromosome 8.
Requesting the test
This test is usually requested by a haematologist or oncologist.
0.5 mL bone marrow in transport media (or 10 mL blood in lithium heparin if blasts>10%).
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
2 business days.
Up to $255.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.